Related Experiment Video

Updated: Apr 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

Cx37 C1019T polymorphism may contribute to the pathogenesis of coronary heart disease

Long Zhao1, Ying Li, Di Wu

  • 11 Department of Respiratory, Central Hospital Affiliated to Shenyang Medical College , Shenyang, People's Republic of China .

Genetic Testing and Molecular Biomarkers
|April 30, 2014
PubMed

Insights

The Cx37 C1019T polymorphism is linked to an increased risk of coronary heart disease (CHD). This genetic variation, particularly the T allele, is a significant risk factor, especially in Chinese populations.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Molecular Biology

Background:

  • Coronary heart disease (CHD) remains a leading cause of mortality worldwide.
  • Genetic factors play a crucial role in the pathogenesis of CHD.
  • The role of specific gene polymorphisms, such as Cx37 C1019T, in CHD risk requires further investigation.

Purpose of the Study:

  • To conduct a meta-analysis of case-control studies.
  • To evaluate the association between the Cx37 C1019T (rs1764391 C>T) polymorphism and the risk of coronary heart disease (CHD).

Main Methods:

  • Comprehensive literature search of multiple databases (MEDLINE, Cochrane Library, EMBASE, CINAHL, Web of Science, CBM) from 1945/1966 to 2013.
  • Meta-analysis of nine case-control studies involving 1426 CHD patients and 929 healthy controls.
  • Calculation of odds ratios (ORs) with 95% confidence intervals (95% CIs) using STATA statistical software.

Main Results:

  • The Cx37 C1019T polymorphism was significantly correlated with an increased risk of CHD.
  • Specific genetic models showed significant associations: T allele vs. C allele (OR=1.63), CT+TT vs. CC (OR=1.86), TT vs. CC+CT (OR=1.81), TT vs. CC (OR=2.50), and TT vs. CT (OR=1.53).
  • Subgroup analysis revealed a strong link between the Cx37 C1019T polymorphism and increased CHD risk in Chinese populations, but not in non-Chinese populations.

Conclusions:

  • The Cx37 C1019T polymorphism is a potential contributing factor to the pathogenesis of coronary heart disease.
  • The association is particularly pronounced among Chinese populations.
  • These findings provide empirical evidence supporting the role of this genetic polymorphism in CHD risk.
Abstract

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K